Case Western Reserve University and Atelerix Life Sciences Inc. have signed a two-year option to license a novel family of small molecules to prevent or reverse life-threatening opioid-related side effects.

HemoShear Therapeutics, Inc. has identified a second drug target for the treatment of gout under its collaboration with Horizon Therapeutics plc.